Buscar
Mostrando ítems 11-20 de 20
Levosimendan en disfunción ventricular en el posoperatorio de cirugía cardíaca. Hospital Santa Clara de Bogotá D.C. Octubre 2011 a Septiembre 2012
(Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud, 2015-12-01)
Polypill with or without aspirin in persons without cardiovascular disease
(The New England Journal of MedicineUSA, 2021-01-21)
BACKGROUND
A polypill comprising statins, multiple blood-pressure–lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease.
METHODS
Using a 2-by-2-by-2 factorial design, we randomly ...
Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
(2016-04-26)
BACKGROUND
Antihypertensive therapy reduces the risk of cardiovascular events among high-risk
persons and among those with a systolic blood pressure of 160 mm Hg or higher,
but its role in persons at intermediate risk ...
Blood-pressure and cholesterol lowering in persons without cardiovascular disease
(2016-04-02)
BACKGROUND
Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially.
METHODS
In ...
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail
(Cardiovascular DiabetologyReino Unido, 2020-11-01)
Background
The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor ...
Cholesterol lowering in intermediate-risk persons without cardiovascular disease
(2016-05-26)
BACKGROUND
Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated ...
Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)
(2016-05)
OBJECTIVE
The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and reduced incident diabetes in high–cardiovascular ...
Novel Approaches in Primary Cardiovascular Disease Prevention : The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
(2016-03)
Résumé
Introduction
Il est possible de faire baisser efficacement et en toute sécurité le cholestérol et la pression artérielle (PA) avec les statines et les antihypertenseurs tout en réduisant de 20 à 30 % les manifestations ...
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
(Oxford AcademicReino Unido, 2021-08-14)
Aims. Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in
12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) ...
Leptina, obesidad y enfermedades cardiovasculares
(Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud, 2020-04-06)